Here for you, every second

Locations

United Kingdom
Kiniksa Pharmaceuticals
International, plc
Kiniksa Pharmaceuticals (UK), Ltd.
Second Floor
105 Piccadilly
London, UK
W1J 7NJ
USA Headquarters
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA 02421 USA
(781) 431-9100
Switzerland
Kiniksa Pharmaceuticals, GmbH
Grafenaustrasse 5
6300 Zug, Switzerland
USA California
Kiniksa Pharmaceuticals Corp.
3366 N. Torrey Pines Court
#320
La Jolla, CA 92037

Utility

Contact Us

Main navigation

About Us
Medicines & Pipeline
Patients & Advocacy
Investors
For Healthcare Professionals
Join Us

Menu

IR navigation

News & Events
Stock Information
- Stock Quote & Chart
- Historical Price Lookup
Financial Information
Corporate Governance
Investor Resources

Press Releases

Year

All
2026
2025
2024

11/12/25

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
10/28/25

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
10/23/25

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
10/17/25

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
08/28/25

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
07/29/25

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
07/24/25

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
06/05/25

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
05/29/25

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
04/30/25

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
04/29/25

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
04/24/25

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
02/25/25

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
02/25/25

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
02/20/25

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
01/13/25

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
01/06/25

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Print Page

RSS

Email Alerts

Search

Image

United Kingdom
Kiniksa Pharmaceuticals
International, plc
Kiniksa Pharmaceuticals (UK), Ltd.
Second Floor
105 Piccadilly
London, UK
W1J 7NJ
USA Headquarters
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA 02421 USA
(781) 431-9100
Switzerland
Kiniksa Pharmaceuticals, GmbH
Grafenaustrasse 5
6300 Zug, Switzerland
USA California
Kiniksa Pharmaceuticals Corp.
3366 N. Torrey Pines Court
#320
La Jolla, CA 92037

Copyright © 2026 Kiniksa Pharmaceuticals
All Rights Reserved. All trademarks mentioned are the property of their respective owners.
Terms of Use | Privacy Policy | Accessibility Statement
|Cookie Policy | Cookie Settings